Resmetirom Introduces New Hope for MASH Treatment

Mar 1, 2025 · Published in: Nature Reviews. Drug Discovery

Background Information

Resmetirom paves the way for new MASH treatments.

Metabolic dysfunction-associated steatohepatitis (MASH) is a growing global health issue with limited treatment options, affecting liver function and overall health. Resmetirom, a thyroid hormone receptor-beta agonist, is the first approved drug for MASH, showing promise alongside lipid metabolism therapies like semaglutide. While resmetirom's approval is significant, further research is needed to understand placebo effects, trial endpoints, fibrosis reversal timeframes, and comprehensive side effect profiles. Resmetirom's approval marks a new era in MASH treatment, highlighting the need for combined therapeutic approaches.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Do A, Zahrawi F, Mehal WZ

Citation: Do A, Zahrawi F, Mehal WZ Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH). Nature reviews. Drug discovery. 2025;24(3):171-189. doi:10.1038/s41573-024-01084-2

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

Deep Analysis Pending

The deep analysis for this article is pending full-text access. We only publish a full clinical breakdown once we have the complete paper, not just the abstract. The PubMed abstract is linked above in the meantime.